Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MHRA Offers Medtechs Extra Transition Time For UK Regulatory System Compliance

UK regulator to allow three- and five-year transitions for CE-marked devices and diagnostics

Executive Summary

26 June saw the release finally of the UK government’s official response to the MHRA’s 2021 consultation on its post-Brexit medical devices regulatory framework. The considered response, held up by political and internal timing issues, represents an implementation plan for reform of the system. Crucially it allows industry extra compliance time.

You may also be interested in...



Tunbridge: Global CABs Are Vital For Global Device Regulation

The role and purpose of medical device regulation is now better understood than at any time in its history, and regulators are no longer seen as gatekeepers preventing business from happening. Graeme Tunbridge, formerly at the MHRA and now a senior VP at leading conformity assessment body BSI, is a champion of the climate of inclusivity.

How Stormy UK Politics Could Intrude On Medtech Regulatory Readiness

The current turmoil at the heart of the UK government is the last thing the medtech industry needs right now as it awaits publication of the new, post-Brexit UK medtech regulations.

UK MHRA Full Steam Ahead On Transformation Plan But Medtech Regulation Still Held Up

Teething troubles including staffing issues and a hold-up in the progress of the post-Brexit medical devices statutory instruments have beset the UK MHRA as it transforms to a new lifecycle-based regulatory agency that puts primacy on patient safety. But there is much to celebrate, says chief executive June Raine.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT145560

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel